Mobile Stroke Units: Current and Future Impact on Stroke Care

Abstract

Ischemic stroke is a leading cause of death and major disability that impacts societies across the world. Earlier thrombolysis of blocked arteries with intravenous tissue plasminogen activator (tPA) and/or endovascular clot extraction is associated with better clinical outcomes. Mobile stroke units (MSU) can deliver faster tPA treatment and rapidly transport stroke patients to centers with endovascular capabilities. Initial MSU trials in Germany indicated more rapid tPA treatment times using MSUs compared with standard emergency room treatment, a higher proportion of patients treated within 60 minutes of stroke onset, and a trend toward better 3-month clinical outcomes with MSU care. In the United States, the first multicenter, randomized clinical trial comparing standard versus MSU treatment began in 2014 in Houston, TX, and has demonstrated feasibility and safety of MSU operations, reliability of telemedicine technology to assess patients for tPA eligibility without additional time delays, and faster door-to-groin puncture times of MSU patients needing endovascular thrombectomy in interim analysis. Scheduled for completion in 2021, this trial will determine the cost-effectiveness and benefit of MSU treatment on clinical outcomes compared with standard ambulance and hospital treatment. Beyond ischemic stroke, MSUs have additional clinical and research applications that can profoundly impact other cohorts of patients who require time-sensitive neurological care.

Keywords

acute stroke - thrombectomy - thrombolysis - prehospital - emergency neurology

Publikationsverlauf

Artikel online veröffentlicht:
28. Januar 2021

• References

• 1 Mozaffarian D, Benjamin EJ, Go AS. et al; Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133 (04) e38-e360
• 2 Rha J-H, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38 (03) 967-973
• 3 Rothwell PM, Coull AJ, Silver LE. et al; Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366 (9499): 1773-1783
• 4 Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369 (05) 448-457
• 5 Jauch EC, Saver JL, Adams Jr HP. et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44 (03) 870-947
• 6 Albers GW, Marks MP, Kemp S. et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378 (08) 708-718
• 7 Nogueira RG, Jadhav AP, Haussen DC. et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378 (01) 11-21
• 8 Saver JL, Fonarow GC, Smith EE. et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013; 309 (23) 2480-2488
• 9 National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
• 10 Hacke W, Donnan G, Fieschi C. et al; ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 (9411): 768-774
• 11 Lees KR, Bluhmki E, von Kummer R. et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375 (9727): 1695-1703
• 12 Marler JR, Tilley BC, Lu M. et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55 (11) 1649-1655
• 13 Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke 2009; 40 (06) 2079-2084
• 14 Yeo LL, Paliwal P, Teoh HL. et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013; 70 (03) 353-358
• 15 Khatri P, Yeatts SD, Mazighi M. et al; IMS III Trialists. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol 2014; 13 (06) 567-574
• 16 Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61 (03) 346-350
• 17 Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J, Goldstein LB. Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001-2004. Stroke 2009; 40 (12) 3845-3850
• 18 Agyeman O, Nedeltchev K, Arnold M. et al. Time to admission in acute ischemic stroke and transient ischemic attack. Stroke 2006; 37 (04) 963-966
• 19 Evenson KR, Foraker RE, Morris DL, Rosamond WD. A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int J Stroke 2009; 4 (03) 187-199
• 20 Messé SR, Khatri P, Reeves MJ. et al. Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology 2016; 87 (15) 1565-1574
• 21 Gonzales S, Mullen MT, Skolarus L, Thibault DP, Udoeyo U, Willis AW. Progressive rural-urban disparity in acute stroke care. Neurology 2017; 88 (05) 441-448
• 22 Joubert J, Prentice LF, Moulin T. et al. Stroke in rural areas and small communities. Stroke 2008; 39 (06) 1920-1928
• 23 Kozera G, Chwojnicki K, Gójska-Grymajło A, Gąsecki D, Schminke U, Nyka WM. Pomeranian Stroke Register collaborators. Pre-hospital delays and intravenous thrombolysis in urban and rural areas. Acta Neurol Scand 2012; 126 (03) 171-177
• 24 Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke 2013; 8 (08) 681-688
• 25 Mullen MT, Wiebe DJ, Bowman A. et al. Disparities in accessibility of certified primary stroke centers. Stroke 2014; 45 (11) 3381-3388
• 26 Adeoye O, Albright KC, Carr BG. et al. Geographic access to acute stroke care in the United States. Stroke 2014; 45 (10) 3019-3024
• 27 Cadilhac DA, Purvis T, Kilkenny MF. et al; New South Wales Strokes Services Coordinating Committee, Agency for Clinical Innovation. Evaluation of rural stroke services: does implementation of coordinators and pathways improve care in rural hospitals?. Stroke 2013; 44 (10) 2848-2853
• 28 Newbury J, Kleinig T, Leyden J. et al. Stroke epidemiology in an Australian Rural Cohort (SEARCH). Int J Stroke 2017; 12 (02) 161-168
• 29 Lin CB, Peterson ED, Smith EE. et al. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. Circ Cardiovasc Qual Outcomes 2012; 5 (04) 514-522
• 30 Fonarow GC, Zhao X, Smith EE. et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014; 311 (16) 1632-1640
• 31 Fonarow GC, Smith EE, Saver JL. et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011; 123 (07) 750-758
• 32 Kim JT, Fonarow GC, Smith EE. et al. Treatment with tissue plasminogen activator in the golden hour and the shape of the 4.5-hour time-benefit curve in the National United States Get With The Guidelines-Stroke Population. Circulation 2017; 135 (02) 128-139
• 33 Van Hooff RJ, Cambron M, Van Dyck R. et al. Prehospital unassisted assessment of stroke severity using telemedicine: a feasibility study. Stroke 2013; 44 (10) 2907-2909
• 34 Itrat A, Taqui A, Cerejo R. et al; Cleveland Pre-Hospital Acute Stroke Treatment Group. Telemedicine in prehospital stroke evaluation and thrombolysis: taking stroke treatment to the doorstep. JAMA Neurol 2016; 73 (02) 162-168
• 35 Fassbender K, Walter S, Liu Y. et al. “Mobile stroke unit” for hyperacute stroke treatment. Stroke 2003; 34 (06) e44
• 36 Walter S, Kostpopoulos P, Haass A. et al. Bringing the hospital to the patient: first treatment of stroke patients at the emergency site. PLoS One 2010; 5 (10) e13758
• 37 Walter S, Kostopoulos P, Haass A. et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 2012; 11 (05) 397-404
• 38 Weber JE, Ebinger M, Rozanski M. et al; STEMO-Consortium. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology 2013; 80 (02) 163-168
• 39 Ebinger M, Kunz A, Wendt M. et al. Effects of golden hour thrombolysis: a Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) substudy. JAMA Neurol 2015; 72 (01) 25-30
• 40 Kunz A, Ebinger M, Geisler F. et al. Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study. Lancet Neurol 2016; 15 (10) 1035-1043
• 41 Ebinger M, Harmel P, Nolte CH, Grittner U, Siegerink B, Audebert HJ. Berlin prehospital or usual delivery of acute stroke care - Study protocol. Int J Stroke 2017; 12 (06) 653-658
• 42 Parker SA, Bowry R, Wu TC. et al. Establishing the first mobile stroke unit in the United States. Stroke 2015; 46 (05) 1384-1391
• 43 Bowry R, Parker S, Rajan SS. et al. Benefits of stroke treatment using a mobile stroke unit compared with standard management: the BEST-MSU study run-in phase. Stroke 2015; 46 (12) 3370-3374
• 44 Wu TC, Parker SA, Jagolino A. et al. Telemedicine can replace the neurologist on a mobile stroke unit. Stroke 2017; 48 (02) 493-496
• 45 Gutiérrez JM, Emery RJ, Parker SA, Jackson K, Grotta JC. Radiation monitoring results from the first year of operation of a unique ambulance-based computed tomography unit for the improved diagnosis and treatment of stroke patients. Health Phys 2016; 110 (5, Suppl 2): S73-S80
• 46 Yamal JM, Rajan SS, Parker SA. et al. Benefits of stroke treatment delivered using a mobile stroke unit trial. Int J Stroke 2018; 13 (03) 321-327
• 47 Ramadan AR, Denny MC, Vahidy F. et al. Agreement among stroke faculty and fellows in treating ischemic stroke patients with tissue-type plasminogen activator and thrombectomy. Stroke 2017; 48 (01) 222-224
• 48 Rumboldt Z, Huda W, All JW. Review of portable CT with assessment of a dedicated head CT scanner. AJNR Am J Neuroradiol 2009; 30 (09) 1630-1636
• 49 Grunwald IQ, Ragoschke-Schumm A, Kettner M. et al. First automated stroke imaging evaluation via Electronic Alberta Stroke Program Early CT Score in a mobile stroke unit. Cerebrovasc Dis 2016; 42 (5-6): 332-338
• 50 Gyrd-Hansen D, Olsen KR, Bollweg K, Kronborg C, Ebinger M, Audebert HJ. Cost-effectiveness estimate of prehospital thrombolysis: results of the PHANTOM-S study. Neurology 2015; 84 (11) 1090-1097
• 51 Dietrich M, Walter S, Ragoschke-Schumm A. et al. Is prehospital treatment of acute stroke too expensive? An economic evaluation based on the first trial. Cerebrovasc Dis 2014; 38 (06) 457-463
• 52 Berkhemer OA, Fransen PS, Beumer D. et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372 (01) 11-20
• 53 Goyal M, Demchuk AM, Menon BK. et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372 (11) 1019-1030
• 54 Goyal M, Menon BK, van Zwam WH. et al; HERMES Collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387 (10029): 1723-1731
• 55 Prabhakaran S, Ward E, John S. et al. Transfer delay is a major factor limiting the use of intra-arterial treatment in acute ischemic stroke. Stroke 2011; 42 (06) 1626-1630
• 56 Czap AL, Grotta JC, Parker SA. et al. Emergency department door-to-puncture time since 2014. Stroke 2019; 50 (07) 1774-1780
• 57 Cerejo R, John S, Buletko AB. et al. A mobile stroke treatment unit for field triage of patients for intraarterial revascularization therapy. J Neuroimaging 2015; 25 (06) 940-945
• 58 Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998; 29 (06) 1160-1166
• 59 Brott T, Broderick J, Kothari R. et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28 (01) 1-5
• 60 Wendt M, Ebinger M, Kunz A. et al; STEMO Consortium. Improved prehospital triage of patients with stroke in a specialized stroke ambulance: results of the pre-hospital acute neurological therapy and optimization of medical care in stroke study. Stroke 2015; 46 (03) 740-745
• 61 Schwindling L, Ragoschke-Schumm A, Kettner M. et al. Prehospital imaging-based triage of head trauma with a mobile stroke unit: first evidence and literature review. J Neuroimaging 2016; 26 (05) 489-493
• 62 Tsalach A, Ratner E, Lokshin S. et al. Cerebral autoregulation real-time monitoring. PLoS One 2016; 11 (08) e0161907
• 63 Wendt M, Ebinger M, Kunz A. et al; STEMO Consortium. Copeptin levels in patients with acute ischemic stroke and stroke mimics. Stroke 2015; 46 (09) 2426-2431
• 64 Rozanski M, Waldschmidt C, Kunz A. et al. Glial fibrillary acidic protein for prehospital diagnosis of intracerebral hemorrhage. Cerebrovasc Dis 2017; 43 (1-2): 76-81
• 65 Bowry R, Nour M, Kus T. et al. Intraosseous administration of tissue plasminogen activator on a mobile stroke unit. Prehosp Emerg Care 2019; 23 (04) 447-452
• 66 Zaidat OO, Changal KH, Sultan-Qurraie A. et al. Diurnal variations in the first 24/7 mobile stroke unit. Stroke 2019; 50 (07) 1911-1914
• 67 Walter S, Zhao H, Easton D. et al. Air-mobile stroke unit for access to stroke treatment in rural regions. Int J Stroke 2018; 13 (06) 568-575
• 68 Phan TG, Beare R, Parsons M. et al. Googling boundaries for operating mobile stroke unit for stroke codes. Front Neurol 2019; 10: 331
• 69 Fassbender K, Balucani C, Walter S, Levine SR, Haass A, Grotta J. Streamlining of prehospital stroke management: the golden hour. Lancet Neurol 2013; 12 (06) 585-596
• 70 Walter S, Grunwald IQ, Helwig SA. et al. Mobile stroke units - cost-effective or just an expensive hype?. Curr Atheroscler Rep 2018; 20 (10) 49
• 71 Audebert H, Fassbender K, Hussain MS. et al; PRESTO Group. The PRE-hospital Stroke Treatment Organization. Int J Stroke 2017; 12 (09) 932-940